S-1 plus oxaliplatin for the treatment of advanced small bowel adenocarcinoma

张慧卿; 何波; 芦珊; 王艳华; 宋荣峰; 万以叶

doi:10.3969/j.issn.1007-3969.2014.01.008

您当前的位置：

首页 >

文章列表页 >

S-1 plus oxaliplatin for the treatment of advanced small bowel adenocarcinoma

更新时间：2025-12-31

- S-1 plus oxaliplatin for the treatment of advanced small bowel adenocarcinoma
- China Oncology Vol. 24, Issue 1, Pages: 46-51(2014)
- 作者机构：
  
  江西省肿瘤医院内三科,江西,南昌,330029
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2014.01.008
  CLC：
- Published Online：14 February 2014，
  
  Published：14 February 2014
- 稿件说明：
移动端阅览
张慧卿,何波,芦珊,王艳华,宋荣峰,万以叶. 替吉奥联合奥沙利铂方案治疗晚期小肠腺癌的临床观察[J]. 中国癌症杂志, 2014, 24(1): 46-51.

张慧卿, 何波, 芦珊, et al. S-1 plus oxaliplatin for the treatment of advanced small bowel adenocarcinoma[J]. China Oncology, 2014, 24(1): 46-51.
张慧卿,何波,芦珊,王艳华,宋荣峰,万以叶. 替吉奥联合奥沙利铂方案治疗晚期小肠腺癌的临床观察[J]. 中国癌症杂志, 2014, 24(1): 46-51. DOI： 10.3969/j.issn.1007-3969.2014.01.008.

张慧卿, 何波, 芦珊, et al. S-1 plus oxaliplatin for the treatment of advanced small bowel adenocarcinoma[J]. China Oncology, 2014, 24(1): 46-51. DOI： 10.3969/j.issn.1007-3969.2014.01.008.

摘要

背景与目的：化疗是晚期小肠腺癌的主要治疗手段，目前尚无标准治疗方案。本研究旨在评估替吉奥联合奥沙利铂治疗晚期小肠腺癌的疗效与安全性。方法：收集29例经替吉奥联合奥沙利铂治疗的晚期小肠腺癌患者的临床资料，并进行回顾性分析。化疗方案：第1天，静脉滴注奥沙利铂130 mg/m

；第1~14天，口服替吉奥40 mg/m

，每日2次，21 d为1个周期。结果：患者完成中位化疗周期数4(2~9)个，均可评估疗效，其中完全缓解(complete response，CR)2例(6.9%)，部分缓解(partial response，PR)9例(31.0%)，客观有效率(response rate，RR)为37.9%，疾病控制率(disease control rate，DCR)为65.5%。无一例患者失访，中位随访时间为14.7个月。患者中位无进展生存时间(progress free survival，PFS)为5.4个月(95%CI:3.6~7.2)，中位总生存时间(overall survival，OS)为13.2个月(95%CI:6.7~19.7)。亚组分析显示，替吉奥联合奥沙利铂方案非一线化疗、体力状况(Eastern Cooperative Oncology Group，ECOG)评分1分，转移部位2个的患者中位OS明显缩短(P0.05)。化疗的主要不良反应为骨髓抑制、胃肠道反应、乏力、周围神经病变和皮疹，以轻度为主，均可耐受。结论：本研究，结果显示，替吉奥联合奥沙利铂治疗晚期小肠腺癌有效率高、耐受性好，值得进一步研究。

Abstract

Background and purpose: Small bowel adenocarcinoma (SBA) is uncommon

and frequently diagnosed at late stage. Chemotherapy is the main treatment method for advanced SBA. Despite recent progress in SBA therapy

no standard regimen has been established up to now

and new active regimen is expected to improve the outcome of this disease. The purpose of this study was to evaluate the efficacy and safety of S-1/oxaliplatin for the treatment of advanced SBA. Methods: In a retrospective study

clinical characteristics and outcomes of 29 patients

with advanced SBA were collected and analyzed. Patients received oral S-1 40 mg/m

twice daily

d1-14

oxaliplatin was administered intravenously 130 mg/m

on the first day of every cycle

repeated every 3 weeks. Efficacy and toxicity were evaluated after at least two consecutive cycles. Results: All patients were evaluated for efficacy and safety. The objective response and disease control rates were 37.9% and 65.5%

respectively. The median progression-free survival and overall survival were 5.4 months (95%CI: 3.6-7.2) and 13.2 months (95%CI: 6.7-19.7)

respectively. In univariate analysis

the following factors were significantly associated with poor outcome: not first line chemotherapy setting

ECOG performance status1 and sites of metastasis2 (Log-rank

P0.05). The treatment related adverse events were mild and manageable. Myelosuppression

gastrointestinal reaction

fatigue

sensory neuropathy and rash were the most common toxicities. Conclusion: This study was the first to report the efficacy of S-1 combined with oxaliplatin for advanced SBA. S-1/oxaliplatin may be effective and safe for advanced SBA and worthy of further study.

关键词

Keywords

references

Views

2872

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Weekly docetaxel combined with cisplatin versus weekly docetaxel combined with oxaliplatin in the treatment of advanced gastric cancer

Chinese expert consensus on whole-process management of chemotherapy-related diarrhea (2025 edition)

Effectiveness and safety analysis of camrelizumab combined with chemotherapy and targeted therapy in patients with recurrent, metastatic, and treatment-naive advanced cervical cancer: a retrospective cohort study

A prospective single-arm study of the efficacy and safety of lobaplatin-based HIPEC combined with optimal support in the treatment of abdominal metastatic cancer

A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer

Related Author

王涛

赵磊

李榆

Association Committee of Rehabilitation and Palliative Care China Anti-Cancer

Association Committee of Cancer Pain Fujian Anti-Cancer

Sumei FAN

Congling XIN

Laifang ZHU

Related Institution

兰州大学第二医院 VIP 外科

Department of Diagnostic Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Diagnostic Radiology, Minhang Branch, Fudan University Shanghai Cancer Center

Department of Gynecological Oncology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College, Fudan University

Department of Pharmacy, Minhang Branch, Fudan University Shanghai Cancer Center

AI问答

⁰